KRAS and lung carcinoma: Consistent with a previous report [18], ARS-1620 initially suppressed ERK phosphorylation and accumulation of KRAS-GTP in both H23 and H358 KRASG12C-mutant lung cancer cells (Fig. 1A–D and Supplemental Material 1).